How 5-Amino-1MQ Actually Works on Fat Cells

Nicotinamide adenine dinucleotide, or NAD+, sits at the center of how your cells make energy, and understanding it is the only way to understand why 5-amino-1MQ does anything at all. Your mitochondria, which are the small energy-generating structures inside nearly every cell in your body, take the food you eat and convert it into something called ATP, which is the actual usable currency of cellular energy. NAD+ functions in this process like a shuttle, picking up electrons that get released when food is broken down and carrying those electrons into something called the electron transport chain, which is a series of protein complexes embedded in the inner mitochondrial membrane. As those electrons move through the chain, they push protons across the membrane, and that gradient of protons is what physically drives the production of ATP. Once NAD+ delivers its electrons, it becomes NADH, and after those electrons are used up generating ATP, the NADH gets converted back into NAD+ so the shuttle can run again. This cycle repeats thousands of times every day in every cell, so if your NAD+ levels drop low enough, the whole system slows down and your cells produce less energy.

Where Your Body Gets NAD+ From

Your body does not rely on a single pathway to make NAD+. It uses several routes, but the most important one, responsible for roughly 80% of total NAD+ production, is something called the salvage pathway, which is a recycling system that takes nicotinamide, a form of vitamin B3, and converts it back into NAD+ through a series of enzymatic steps. The first and rate-limiting enzyme in this pathway is something called NAMPT, which stands for nicotinamide phosphoribosyltransferase, and it has an extremely high affinity for nicotinamide, meaning it captures and processes nicotinamide very efficiently under normal conditions.

Because vitamin B3 can also be obtained from food and supplements in relatively large amounts, the body has a separate clearance system to prevent nicotinamide from accumulating to levels that would cause problems. That clearance system depends on an enzyme called NNMT, which stands for nicotinamide N-methyltransferase, and what it does is take nicotinamide and attach a methyl group to it through a process called methylation, converting nicotinamide into a waste compound that gets excreted in urine. NNMT is not a malfunction and it is not a foreign substance, it is a normal part of human physiology doing exactly what it evolved to do, which is clear out excess nicotinamide when the body has more than it needs.

The Problem That Develops in Fat Tissue

Under normal conditions in the liver, where NNMT is strongly expressed, this clearance activity does not create a meaningful problem for NAD+ production because the liver has access to multiple NAD+ synthesis pathways beyond just the salvage pathway. But adipose tissue, which is the technical name for the fat stored in your body, is a different environment because fat cells depend almost entirely on the salvage pathway to generate their NAD+, and NNMT is the only enzyme in fat cells that breaks down nicotinamide in a catabolic direction. So in adipose tissue, NNMT and NAMPT are essentially in direct competition for the same substrate, and normally NAMPT wins that competition because it has an affinity for nicotinamide that is approximately 430 times higher than NNMT's affinity.

The situation changes when someone develops obesity, because excess body fat drives something called NNMT overexpression in adipose tissue, meaning fat cells start producing far more of the NNMT enzyme than they would under lean conditions. When NNMT activity rises to pathologically elevated levels, it can overcome NAMPT's natural advantage and begin pulling a significant portion of the available nicotinamide away from NAD+ synthesis and toward excretion. This creates a deficit of NAD+ specifically inside fat cells, and because NAD+ is essential for the mitochondrial energy production process, fat cells with depleted NAD+ become less capable of burning stored fat for fuel and shift toward storing more. The result is a self-reinforcing cycle where more body fat leads to more NNMT expression, which depletes NAD+ in fat tissue, which impairs the fat cells' ability to burn energy, which promotes further fat accumulation, which further increases NNMT expression.

What 5-Amino-1MQ Actually Does

5-amino-1MQ is a small synthetic molecule that functions as a selective NNMT inhibitor, meaning it binds to the NNMT enzyme and blocks it from methylating nicotinamide. By reducing NNMT activity specifically in adipose tissue where it is pathologically overexpressed, 5-amino-1MQ allows more nicotinamide to flow through the salvage pathway toward NAD+ production inside fat cells, which restores mitochondrial energy capacity and shifts those cells back toward fat oxidation rather than fat storage. Animal research using diet-induced obese mice demonstrated a roughly 35% reduction in body mass and a 30% decrease in fat cell size without any change in food intake, and the mechanism behind those results was increased energy expenditure rather than appetite suppression. This is an important distinction because it means the compound was restoring a metabolic function that had been impaired by elevated NNMT, not simply making animals eat less.

The research also makes clear that the relationship between NNMT overexpression and body composition correlates more strongly with the amount of adipose tissue present than with age specifically. This means the mechanism of 5-amino-1MQ is fundamentally corrective rather than universally enhancing, and the target population based purely on the biology is people who have metabolic dysfunction tied to excess body fat, not lean individuals looking for performance optimization. If adipose NNMT is not pathologically overexpressed, there is no significant drain on the salvage pathway to correct, and blocking an enzyme that is already operating at baseline levels produces little functional benefit.

Why Most Dosing Protocols Do Not Match the Pharmacology

The animal research that demonstrated significant fat loss used doses that translate to approximately 400 milligrams per day for a human adult when converted through something called allometric scaling, which is a method for adjusting doses between species based on differences in body weight and metabolic rate. Most protocols circulating online suggest oral doses of 50 to 150 milligrams per day, or subcutaneous doses of 50 to 100 milligrams per day, and some go even lower, suggesting microdosing at quantities between 150 and 600 micrograms per day. The spread between the lowest suggested microdose and the scientifically derived effective dose is roughly 2,500-fold, which is not a minor discrepancy.

Understanding why this matters requires a concept called IC50 coverage, which refers to the concentration of a drug that needs to be present in tissue to inhibit at least 50% of its target enzyme. Below the IC50 threshold, a drug is not producing meaningful inhibition regardless of how many days you take it, because enzyme inhibition requires achieving a minimum active concentration at the site of action. To estimate what concentration 5-amino-1MQ needs to reach, it is useful to compare it to metformin, which shares similar molecular weight, carries a similar positive charge, and has comparable oral bioavailability and half-life. Based on metformin's pharmacokinetic profile, oral doses of 50 to 150 milligrams per day of 5-amino-1MQ appear plausible for partial NNMT inhibition, and doses in the 400 to 600 milligram per day range would align with near-complete inhibition consistent with the translated mouse dose.

A 150 microgram daily microdose lands approximately 400 times below the estimated IC50 threshold, and the lowest concentration shown to produce any measurable increase in NAD+ in the research literature was roughly 1,000 times higher than what microdoses achieve. The argument sometimes made for microdosing is that even minimal NNMT inhibition preserves some NAD+ and provides subtle support, but this reasoning runs into the biological reality that NAMPT already preferentially captures nicotinamide under normal conditions, so a trivial reduction in NNMT activity in someone who does not have pathological overexpression changes the effective NAD+ balance very little. For someone who genuinely wants NAD+ support without excess body fat or NNMT overexpression, direct supplementation with precursors like NMN or injectable NAD+ delivers substrate to the pathway far more directly and efficiently than a sub-threshold inhibitor dose.

The Economics Behind Sub-Therapeutic Dosing

The reason microdosing protocols persist despite being pharmacologically inconsistent has a straightforward economic explanation. A 10 milligram vial of 5-amino-1MQ used at 150 micrograms per day lasts approximately 66 days, while the same vial used at a therapeutically relevant dose of 5 milligrams per day would last only two days. Running a proper dose for any meaningful duration would cost far more than most individuals using research compounds are willing or able to spend, so the doses people actually use are shaped by what is affordable rather than what the pharmacology requires. Some users report modest results at lower doses, and those anecdotal reports circulate and reinforce protocols that may be producing little to no meaningful enzyme inhibition, because personal reports cannot distinguish between placebo response, confounding lifestyle factors, and actual pharmacological effect.

How Oral Versus Subcutaneous Administration Changes the Math

5-amino-1MQ is classified as a small molecule rather than a peptide, which means it is stable enough to survive the digestive process without being broken down before it can be absorbed, so it can be taken orally. However, oral administration comes with something called bioavailability, which refers to the fraction of a dose that actually reaches systemic circulation after absorption and first-pass metabolism. For 5-amino-1MQ, oral bioavailability is estimated at approximately 38%, meaning that just over one-third of an oral dose reaches the bloodstream. Subcutaneous injection bypasses the digestive system entirely, so a greater proportion of the dose reaches circulation, which is why subcutaneous doses can be lower than oral doses while still achieving similar or higher effective concentrations in tissue. At doses of 50 to 100 milligrams per day given subcutaneously, the systemic exposure is meaningfully higher than the same oral dose would provide, and for people pursuing more aggressive effects, higher oral doses become necessary to compensate for that absorption gap.

Where This Compound Fits Within a Broader Protocol

Within a structured approach to metabolic optimization, 5-amino-1MQ functions as a pathway-specific intervention rather than a foundational supplement, and its role makes most logical sense alongside direct NAD+ support because it reduces the enzymatic drain that would otherwise compete with NAD+ precursor supplementation. If someone is using SS31, which is a compound that targets structural damage in the mitochondrial membrane, alongside NAD+ supplementation, adding 5-amino-1MQ at effective doses helps ensure that the nicotinamide being supplied to the system is directed toward NAD+ synthesis in fat tissue rather than being cleared by overexpressed NNMT. The same logic applies when combining it with compounds like MOTC that support mitochondrial biogenesis, because preserving the NAD+ substrate available to those mitochondria amplifies the overall effect.

Consistency matters as much as dose selection because NNMT inhibition needs to be maintained continuously to sustain the shift in nicotinamide metabolism, and intermittent or irregular dosing would allow NNMT activity to recover between administrations and reduce the cumulative impact on NAD+ levels in adipose tissue.

---

References

1. Gusenbauer M, Haddaway NR. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. Res Synth Methods. 2020. Source
2. Lindsey WT, Olin BR. PubMed searches: overview and strategies for clinicians. Nutr Clin Pract. 2013. Source
3. Pirani C, Camilleri J. Effectiveness of root canal filling materials and techniques for treatment of apical periodontitis: A systematic review. Int Endod J. 2023. Source
4. Damen MS, Alarcon PC, Chan CC et al.. A shift in PKM2 oligomeric state instructs adipocyte inflammatory potential. JCI Insight. 2025. Source
5. She J, Sheng R, Qin ZH. Pharmacology and Potential Implications of Nicotinamide Adenine Dinucleotide Precursors. Aging Dis. 2021. Source
6. Hattori K, Kobayashi K, Azuma-Suzuki R et al.. Nicotinamide phosphoribosyl transferase in mammary gland epithelial cells is required for nicotinamide mononucleotide production in mouse milk. Biochem Biophys Res Commun. 2024. Source
7. Tedesco L, Corsetti G, Ruocco C et al.. A specific amino acid formula prevents alcoholic liver disease in rodents. Am J Physiol Gastrointest Liver Physiol. 2018. Source
8. Li Y, Wong K, Giles A et al.. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology. 2014. Source
9. Wang L, Teng R, Di L et al.. PPARα and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders. Diabetes. 2013. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness